DEPLOYDatabase

Robot model

Lingo

Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform,…

Track Lingo
Manufacturer
Abbott
Form factor
biometric
Maturity
commercial
Lifecycle
active
Deployments
1
Website
abbott.mediaroom.com ↗

Overview

Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Verified deployments
1 deployment on file
Sources on file
3 sources, view all

Key facts

Runtime

up to 14 days

Price

~$54 for a 2-week single-biosensor starter plan

Sensor suite

glucose-oxidase amperometric assay

Autonomy level

FDA-cleared OTC Class II integrated CGM for adults 18+ not on insulin

Form factor

disposable biosensor worn on the back of the upper arm

Availability

Commercial — OTC, no prescription needed, abbott.com and pharmacies

Pricing model

Monthly subscription ($49/month for 2 sensors, 15-day wear each)

Specs

Notes

Boundary INCLUDE (narrow) - glucose-biometric + adaptive insight layer: Glucose is in the biometric definition; Lingo is biometric-primary (interstitial glucose). It clears the medical-sensor-without-meaningful-AI exclusion bar on INSIGHT-LAYER substance: Lingo Count with adaptive targets, algorithm-driven personalized food-response recommendations, and Challenges are the differentiator vs a bare CGM graph (which Abbott deliberately does not sell to this wellness audience). Would it exist without the insight layer? Yes-and-meaningfully-degraded -> above the thin-AI floor. Second example of the GLUCOSE cell alongside Stelo., Cap-flag: NOT at Stelo parity (AI is adaptive/algorithmic, NOT verified generative): Critical distinction: Dexcom Stelo cleared the bar with a GENUINE generative-AI layer (Google Cloud Vertex AI + Gemini Weekly Insights). Lingo's primary sources describe adaptive / rule-based personalization only - no documented generative-AI layer, no 'Lingo Coach' AI agent (coaching is algorithmic plus human nutritionist via Lingo Live). Do NOT grant Lingo Stelo-equivalent AI standing. It passes on insight-layer substance, not on generative-AI grounds; this is the borderline case of the cohort and is flagged as such., FDA anchor: FDA 510(k) K233655 decided May 29 2024; OTC integrated CGM; adults 18+ not on insulin; explicitly not for diagnosis of any disease. Directly parallel to Stelo's OTC posture (Stelo = De Novo Mar 2024). Cleared via 510(k) (Stelo via De Novo) - both are OTC wellness clearances., Claimed but NOT verified: Any AI comparable to Stelo's generative AI (not verified - adaptive/rule-based only); a named 'Lingo Coach' AI agent (does not exist); exact stale tier table ($49/$89 figures - verified entry is ~$54/2-week, time-sensitive); any generative-AI roadmap for Lingo (none announced, unlike Dexcom).

Specs

Lingo: over-the-counter continuous glucose monitor (CGM) biosensor for non-diabetic / wellness consumers, built on Abbott's FreeStyle Libre sensor platform. Disposable biosensor worn on the back of the upper arm, up to 14-day wear, glucose-oxidase amperometric assay. FDA 510(k) K233655 decided May 29 2024 (announced Jun 10 2024); Class II integrated CGM (21 CFR 862.1355); indication: adults 18+ NOT on insulin; explicitly NOT for diagnosis of any disease including diabetes. App: real-time glucose graph, 'Lingo Count' daily glucose-spike metric with adaptive targets, food/activity logging, algorithm-driven personalized recommendations, 'Lingo Challenges' behavioral nudges, and 'Lingo Live' (free ~30-min sessions with human Abbott nutritionists). Pricing: entry ~$54 for a 2-week single-biosensor starter plan, recurring biweekly/monthly multi-sensor tiers. Maker: Abbott (NYSE: ABT), Abbott Diabetes Care.

Form Factor

biometric (biometric-primary GLUCOSE biosensor / OTC continuous glucose monitor + adaptive insight layer; second glucose example alongside Stelo)

Fda clearance

Source: fda.gov Status: cleared; Details: FDA-cleared OTC biosensor (K241163, June 2024). General wellness use for tracking glucose, ketones, lactate. NOT indicated for diabetes management.; Audited at: 2026-06-07; Source name: FDA; Health claim: Metabolic tracking for wellness optimization. FDA-cleared but explicitly NOT a medical device for disease management.; Verification posture: verified

Data & sources

Press releases

1

Government records

1

Web sources

1

3 sources backing this record.View all →

Availability and pricing

Availability
Shipping now
Price
$54 (actual sale price)as of 2024-06-10
Units in field
Not disclosed
Sales model
Not disclosed
Lead time
Not disclosed

Pricing

One-time purchase

$54 USDactual sale priceas of 2024-06-10

Source: Abbott (Lingo)

Price status: actual-sale-price = real published price at time of sale; manufacturer-target = vendor target, not yet realized; analyst-estimate = third-party projection, not a vendor figure; not-announced = no price on record.

Prices verified as of Jun 10, 2024

Deployments (1)

Lingo on the deployment map

Where Lingo is verified operating. Explore the deployment map by place and type.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Deployment-verified media (1)

PRIMARY SOURCE
Courtesy of Abbott

Abbott's introduction of Lingo, its over-the-counter glucose biosensor. Lingo is FDA-cleared OTC (2024) for consumer wellness and metabolic-health tracking, not diabetes medical management, distinct from the prescription FreeStyle Libre.

From deployment: Global

Regulatory filings (2)

Safety record

No incidents on record for Lingo.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (3)

  1. https://abbott.mediaroom.com/2024-06-10-Abbott-Receives-FDA-Clearance-for-Two-Over-the-Counter-Continuous-Glucose-Monitoring-Systems
  2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K233655
  3. https://www.hellolingo.com/

Compare Lingo

Common questions

What is Lingo?
Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.
How much does Lingo cost?
Lingo is listed at $54 on the DEPLOY registry. This is an actual sale price on record.
Abbott (Lingo)
Is Lingo actually deployed in the real world?
Yes. Lingo is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes Lingo?
Lingo is made by Abbott, based in Abbott Park, IL, founded in 1888.
Where is Lingo deployed?
1 verified deployment of Lingo is on the DEPLOY registry, including at Global.
Methodology: Verified · 3 sources (2 primary) · last reviewed 2026-07-18

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-07-18

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: biometric

Sub-cohorts: glucose-cell-ai-substance-gradient

Sources by quality tier

1
unclassified
Unclassified source
1
primary-fda-database
FDA database
1
primary-company-ir
Company IR disclosure

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Lingo.

Recent coverage

Lingo in third-party press

Ultrahuman launches M2 Live with Abbott's Lingo glucose sensor - t2ONLINE

Jun 18, 2026

Withings Partners With Abbott To Integrate Lingo OTC Glucose Monitoring Data - insights.citeline.com

Jan 6, 2026

Abbott First To Offer OTC Continuous Glucose Monitor On Amazon - insights.citeline.com

Feb 27, 2025